Skip to main content

Advertisement

Table 4 Results of Cox model for progression-free and overall survival

From: Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

   Progression-free survival Overall survival
   HR 95 % CI P HR 95 % CI P
Age ≤60 years 1      
>60 years 1.484 0.969-2.272 0.070 1.236 0.770-1.984 0.379
Smoking Never       
Ever 1.080 0.496-2.353 0.846 1.076 0.465-2.494 0.864
Performance status ECOG 0       
ECOG 1-2 1.110 0.661-1.862 0.694 2.381 1.215-4.673 0.012
Prior surgery No       
Yes 0.799 0.512-1.246 0.322 0.608 0.361-1.024 0.061
Prior radiotherapy No       
Yes 0.924 0.555-1.541 0.763 0.741 0.398-1.379 0.345
Prior chemotherapy No       
Yes 0.839 0.440-1.602 0.595 1.111 0.577-2.410 0.752
No. of metastases One       
≥Two 1.181 0.777-1.795 0.436 1.698 1.059-2.717 0.028
Lung metastasis No       
Yes 1.119 0.624-1.764 0.858 1.201 0.701-2.012 0.488
Liver metastasis No       
Yes 1.235 0.650-2.347 0.520 1.397 0.497-1.838 0.544
Treatment CC       0.219
CP 0.786 0.515-1.198 0.263 0.745 0.465-1.192
  1. CC capecitabine plus cisplatin, CP capecitabine plus paclitaxel